Overview of Nitozol

This overview defines the identity, classification, and general purpose of the medicine Nitozol, which contains the active ingredient Ketoconazole, strictly excluding specific usage instructions or safety warnings.

Quick Facts

Property	Description
Active ingredient	Ketoconazole (a synthetic imidazole derivative)
Form	Available as oral tablets, cream, gel, and topical solution/shampoo
Pharmacological class	Antimycotic agent (azole antifungal group)
General purpose	To control and eliminate pathogenic fungal and yeast infections
Origin	Synthetic compound

What Type of Medicine is Nitozol and Its Active Ingredient?

Nitozol is a medicinal preparation whose active ingredient is Ketoconazole, a drug used to combat fungal and yeast infections. It is classified as an antimycotic agent, belonging to the azole antifungal group. The substance Ketoconazole is a synthetic imidazole derivative, representing a key compound in managing conditions caused by fungal overgrowth.

The drug's properties and mechanism of action are consistent with those of the azole family, which work by disrupting fungal cell function. This action is utilized for its established role in dermatology and the management of systemic mycoses.

Composition, Forms, and Administration Type

Nitozol is a single active ingredient medication supplied in various pharmaceutical forms, allowing for both oral (systemic) and topical (localized) administration. The available forms include oral tablets for internal use, alongside cream, gel, and topical solution/shampoo preparations, which are used for conditions like skin mycoses or dandruff. This range allows the medicine to be delivered directly to the site of infection or absorbed internally.

How Does Nitozol Generally Achieve Its Purpose?

Nitozol's general mechanism works by compromising the fundamental structure of the fungal cell membrane, which either stops the fungus from multiplying or kills the cell. The general purpose of this action is the targeted control of fungal pathogens. Ketoconazole achieves this by interfering with the fungus's ability to produce ergosterol, a critical molecule required for maintaining the integrity of its cell wall. This disruption affects the fungal cell's ability to grow and survive.

What side effects are possible with Nitozol?

Possible side effects and safety information

The safety profile for Nitozol is structured by its different forms, with systemic (oral) use associated with serious, high-level risks, while topical use involves primarily localized reactions. All documented adverse reactions and safety characteristics are based strictly on official regulatory labeling.

Systemic Safety Concerns (Oral Tablets)

The systemic safety profile is dominated by the risk of severe hepatotoxicity, including cases of fatal hepatic failure, which is explicitly documented in official warnings. This risk is generally noted as being highest during the initiation of treatment and within the first six months of exposure. The oral form is formally contraindicated in individuals with acute or chronic liver disease.

Another major safety constraint is the potential for serious endocrine disorders, specifically adrenal insufficiency (hypocortisolism), which is a noted risk for the oral formulation.

Serious Adverse Reactions

System-Organ Class	Serious Adverse Reaction	Regulatory Status
Hepatobiliary	Fatal Hepatic Failure	Explicitly Documented
Cardiac	QTc Interval Prolongation	Warning/Restriction

Frequency-Classified Effects

Common adverse reactions officially documented for the oral tablets often relate to gastrointestinal disorders (such as nausea and vomiting), as well as general skin reactions like pruritus (itching) and rash.

For the topical forms (cream, shampoo), the effects are generally localized to the site of application. Common reactions include local effects like application site pruritus, erythema (redness), and a skin burning sensation, reflecting minimal systemic absorption as noted in regulatory monographs.

Safety-Related Restrictions

Oral use is strictly contraindicated with a defined list of medications that prolong the QTc interval, due to the regulatory-documented risk of life-threatening ventricular dysrhythmias. Furthermore, the use of the oral tablet is generally restricted by regulators to treating specific severe systemic fungal infections when safer alternatives are unavailable.

Overdose and Emergency Response

Overdose and when to seek help

Nitozol (Ketoconazole) overdose carries a documented risk of severe systemic toxicity, primarily affecting the hepatic and cardiovascular systems. Documented manifestations of overdose or high exposure include signs of acute liver injury such as persistent nausea and vomiting, jaundice (yellowing of the skin or eyes), dark urine, and abdominal pain. Overdose is also officially associated with QTc interval prolongation, which can lead to potentially life-threatening ventricular dysrhythmias, including Torsades de pointes. Neurological signs such as seizure and collapse are also noted in regulatory information.

In the event of suspected overdose, specific emergency actions are mandated by regulatory authorities. Immediate contact with emergency services (e.g., 911) is required if the person experiences collapse, a seizure, or trouble breathing, or if they cannot be awakened. Urgent medical attention must also be sought immediately upon the observation of any signs of liver injury.

Overdose management is officially characterized as symptomatic and supportive treatment, reflecting that no specific antidote is known. Procedural steps may include gastric lavage and the administration of activated charcoal, particularly if the ingestion was recent. Due to the risk of severe outcomes, including the potential for liver transplantation, hospital monitoring for cardiac and hepatic function may be required.

Therapeutic Uses of Nitozol

What Nitozol treats: main uses and benefits

Nitozol is commonly used in situations involving certain distressing symptoms related to fungal and yeast overgrowth. It is relevant for addressing several dermatological conditions, providing symptomatic relief across key domains. The medication helps manage symptoms associated with superficial fungal infections like ringworm, athlete's foot, jock itch, and tinea versicolor, as well as chronic conditions such as seborrheic dermatitis and severe dandruff.

The medication is relevant for easing symptoms related to inflammatory or irritative states of the skin. It helps address symptom clusters that may become intense or disruptive, such as persistent flaking, scaling, and pruritus. This contributes to easing daily comfort during periods of heightened symptoms. In highly restricted clinical settings, the oral form is reserved for treating certain severe, deep-seated fungal infections.

“This use is considered relevant for symptomatic support in contexts involving heightened systemic burden when safer alternatives are not available or tolerated.”

Quick Fact: Relief for Skin and Scalp Discomfort
Conditions	Superficial mycoses, chronic dermatitis
Symptom Focus	Scaling, flaking, redness, and itching
Patient Benefit	Supports easing overall symptom burden

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nitozol — Official Regulatory Information

Nitozol (Ketoconazole oral tablets) is subject to strict limitations and contraindications based on authoritative regulatory documentation. Its use is generally restricted to patients with serious systemic fungal infections only when alternative therapies are unavailable or not tolerated.

Eligibility Scope

Category	Regulatory Status
Populations Allowed (Restricted)	Adults with serious systemic fungal infections when alternatives fail; Adults/Adolescents (over 12) for specific hormonal conditions (where approved).
Contraindicated Populations	Patients with Acute or Chronic Liver Disease or known Hypersensitivity to the drug.
Pregnancy and Lactation	Contraindicated for use in pregnant or breastfeeding women.

Eligibility-Related Restrictions

Age-Related Rule: Safety and efficacy have not been established in children younger than 12 years of age. Data in older adults are limited.
Condition Restrictions: The medicine is contraindicated in patients with congenital or acquired QTc prolongation or who are taking specific interacting medications that increase this cardiac risk.
Conditional Use: Patients with adrenal insufficiency or those under prolonged periods of stress (e.g., major surgery) require monitoring of adrenal function as stated in the label.
Non-Recommended Use: The medicine is not indicated for common superficial fungal infections (e.g., onychomycosis, cutaneous Candida infections).

Connection to the overall eligibility profile: Official regulatory documents strictly define the eligible population by establishing numerous absolute contraindications related to liver and cardiovascular function. This profile explicitly excludes most potential users and mandates close physiological monitoring for those few who qualify, reflecting the drug's constrained benefit-to-risk profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nitozol (Ketoconazole) possesses a significant potential for pharmacokinetic interactions that are officially documented in regulatory information. The medicine is classified as a potent inhibitor of the metabolic enzyme Cytochrome P450 3A4 (CYP3A4), which causes substantial changes in the blood concentrations of co-administered drugs.

Documented High-Risk Combinations and Restrictions

Co-administration is formally contraindicated with numerous medicines whose metabolism is affected by CYP3A4 inhibition. This category includes antiarrhythmics (e.g., dofetilide, quinidine), oral benzodiazepines (e.g., oral midazolam), certain HMG-CoA reductase inhibitors (simvastatin, lovastatin), and ergot alkaloids. These combinations carry a risk of severe toxicity, such as QT prolongation or rhabdomyolysis.

Interaction Type	Examples of Affected Co-administered Drugs
Increased Exposure	Cyclosporine, tacrolimus, atorvastatin, warfarin
Reduced Efficacy	Rifampin, rifabutin, isoniazid (via enzyme induction)

Administration and Substance Constraints

The absorption of oral Nitozol is dependent on gastric acidity. To manage this requirement, regulatory documents mandate timing separation rules for co-administration with acid-reducing agents (antacids, H2-antagonists). Antacids must be administered at least two hours after Nitozol tablets. Furthermore, alcohol (ethanol) is restricted due to the official documentation of an increased risk of additive liver toxicity.

Mechanism of Action

How Nitozol Works

Nitozol exerts its effect through two distinct pharmacodynamic mechanisms, beginning with a primary action targeting foreign organisms. The main process involves the targeted inhibition of lanosterol 14alpha-demethylase, a cytochrome P450 enzyme critical for the synthesis of ergosterol. Ergosterol is an essential structural component of the target organism's cell membrane. The blockade of this enzyme leads to the accumulation of toxic intermediary sterol compounds and ultimately causes structural failure and cellular breakdown in the organism. This mechanistic cascade results in the organism's elimination, which reduces its viable population.

Separately, Nitozol exhibits a secondary, concentration-dependent mechanism by inhibiting other cytochrome P450 enzymes in the host body. This enzyme inhibition modulates the synthesis rate of certain endogenous steroid hormones, such as cortisol. The physiological outcome is a measurable alteration in the circulating concentration of these regulatory compounds, reflecting the drug's systemic enzyme interaction.

Dosage and Administration Information

How Nitozol Is Used: Official Administration Guidelines

Nitozol (ketoconazole) is administered via two primary routes: oral for systemic treatment and topical for localized use. The official administration guidelines define specific regimens and conditions for each route, based strictly on regulatory documents.

Oral Use (200 mg Tablets)

Indication Context	Standard Dosing Regimen	Frequency & Conditions
Systemic Fungal Infections	Starting dose: 200 mg daily. May be increased to a maximum of 400 mg daily.	Taken once daily; optimal absorption requires tablets to be taken with food.
Cushing's Syndrome	Initial dose: 400 mg to 600 mg daily; maintenance up to 1,200 mg daily.	Taken in two or three divided doses. Treatment must be supervised by specialists.

For pediatric patients 2 years of age and older, the dose for systemic fungal infections is calculated based on body weight, typically in the range of 3.3 to 6.6 mg/kg/day. No specific dosage modifications for renal or hepatic impairment are provided in manufacturer labeling. If a dose is missed, it should be taken as soon as possible, or skipped if it is near the time for the next scheduled dose.

Topical Use (Cream, Shampoo, etc.)

Topical forms (e.g., 2% cream, 1% or 2% shampoo) are applied externally only to the affected area and its immediate surroundings. The frequency and duration of use are specific to the treated condition:

For skin infections (tinea, cutaneous candidiasis): Applied once daily. The duration may range from 2 to 6 weeks.
For seborrheic dermatitis: The cream or foam is typically applied twice daily for a course lasting up to 4 weeks. Shampoo may be used every 3 or 4 days, followed by use as needed for control.

Contact with the eyes, nose, mouth, or vagina must be avoided during topical application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitozol (Ketoconazole)

Evidence for Topical Use in Superficial Fungal Infections

Nitozol has been studied for conditions characterized by fluctuating or episodic manifestations, such as common fungal skin infections. Research for this use is based primarily on short-term, randomized controlled trials (RCTs). These studies were designed to evaluate the topical formulations against a non-medicated vehicle or other active antifungal ingredients.

The trials explored endpoints such as Therapeutic Cure, which was defined in the study protocol as a specific combination of negative fungal culture (mycological cure) and low scores on symptom scales (clinical cure). Findings describe patterns observed in these studies, reporting the status of the measured outcomes at a final evaluation point.

Evidence for Topical Use in Seborrheic Dermatitis and Severe Dandruff

Research examining Nitozol topical solution or shampoo for seborrheic dermatitis has been applied in studies exploring short-term symptom changes. These studies examined adult and adolescent populations experiencing conditions involving periods of heightened symptoms, such as scaling and itching. Researchers studied outcomes related to physical discomfort, focusing on objective scales to monitor the change in key symptoms: Erythema (redness), Scaling (flaking), and Pruritus (itching). The studies describe patterns observed in how these symptom measures were recorded in the observed populations during the short study period.

Evidence for Oral Use in Highly Restricted Clinical Situations

The oral tablet form of Nitozol has been studied for certain highly restricted conditions, primarily severe endemic systemic mycoses and the study of excessive cortisol production in endogenous Cushing syndrome. For systemic fungal infections, the evidence is largely historical, derived from older clinical trials. The use of oral Nitozol for these conditions is highly regulated; the research context is typically limited to situations where other therapies have been considered or not tolerated.

Areas of Research Uncertainty and Gaps

For topical uses, while short-term evidence exists, the main gap is the lack of robust, long-term research characterizing relapse patterns and research into strategies for studying long-term patterns. Comparative evidence is lacking in certain scenarios. For the highly restricted oral indications, a key area of uncertainty involves the absence of large-scale, prospective, randomized controlled trials; certainty remains low for the historical evidence base. Research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Frequently Asked Questions (FAQ)

Common questions about Nitozol (FAQ)

Q: What are the most common side effects people report when using Nitozol?

A: According to official product information, common adverse reactions for the oral tablets include gastrointestinal issues such as nausea, vomiting, and abdominal pain, as well as skin reactions like itching (pruritus) and rash. When Nitozol is used topically, the most frequently reported reactions are localized, such as a skin burning sensation, redness (erythema), and itching at the application site.

Q: What is the long-term safety profile of Nitozol?

A: Regulatory documents emphasize that the risk of severe liver damage (hepatotoxicity) associated with oral Nitozol is generally highest when treatment begins and within the first six months. The official documentation indicates that data characterizing the long-term safety profile beyond the initial period is limited or not extensively detailed. For topical uses, research has noted a gap in robust, long-term studies.

Q: How long do most people stay on Nitozol treatment?

A: Topical treatments for conditions like skin infections typically last for short periods, such as between two to six weeks. For the highly restricted oral tablets, the duration of therapy is not standardized and must be individually determined under specialist supervision.

Q: What symptoms indicate that I should stop taking Nitozol immediately?

A: Official warnings note that signs of severe adverse reactions associated with the oral tablet may indicate the need for prompt medical review or cessation. These include symptoms of liver problems, such as unusual fatigue, jaundice, dark urine, or pale stools. A prompt medical evaluation is also advised if symptoms suggesting changes in heart rhythm, such as dizziness or an irregular heartbeat, are experienced.

Q: What were the key findings in the initial research trials for Nitozol?

A: Studies involving the oral tablet for specific conditions like Cushing's syndrome reported findings that included a normalization of urine cortisol levels in a number of the observed patients. Trials for topical Nitozol were designed to evaluate specific endpoints like achieving Therapeutic Cure, which includes both mycological and clinical improvement.

Q: Is Nitozol safe to take with common pain relievers like ibuprofen?

A: Regulatory documents do not specifically list common pain relievers like ibuprofen. However, Nitozol is officially categorized as a potent inhibitor of the CYP3A4 metabolic enzyme. This inhibition means there is potential for it to increase the concentration of many co-administered medicines, including certain pain relievers.

Q: Does alcohol consumption interfere with Nitozol?

A: The consumption of alcohol (ethanol) is restricted during treatment with oral Nitozol. This restriction is based on an increased risk of additive liver toxicity. Some regulatory reports also note the possibility of a disulfiram-like reaction, which can cause symptoms such as flushing and nausea.

Q: Does Nitozol cause weight gain or weight loss?

A: Official regulatory documents list both loss of appetite (anorexia) and increased appetite as reported adverse reactions for the oral tablets. However, the official product information does not directly state that Nitozol causes weight gain or weight loss.

Q: Can Nitozol affect my sleep patterns?

A: Official regulatory labeling indicates that the oral tablet may affect sleep patterns. Reported adverse reactions include both insomnia (difficulty sleeping) and somnolence (drowsiness).

Q: Is it normal to feel a bit dizzy when first starting Nitozol?

A: Dizziness is included as an adverse reaction that has been reported with the use of the oral tablet. This side effect may occur, particularly when treatment is first initiated.

Q: Has Nitozol been studied in children or teenagers?

A: Studies have been conducted that support the use of the oral tablet in adolescents over 12 years of age for specific hormonal conditions. However, safety and effectiveness data for the oral tablet have not been established in children younger than 2 years of age, and safety data for the topical cream is not established for children 17 years and younger.

Q: Are there any known issues with taking Nitozol and caffeine?

A: While regulatory documents do not specifically mention caffeine, Nitozol is a potent inhibitor of the CYP3A4 enzyme, which is responsible for metabolizing caffeine. This interaction means there is a potential for higher caffeine levels to occur in the body.

Q: Can Nitozol cause any changes in mood or anxiety levels?

A: Official regulatory labeling for the oral tablet lists nervousness as a reported psychiatric disorder adverse reaction. This suggests the medicine has the potential to cause changes in certain mood or anxiety-related states.

Q: Do I need to avoid any specific foods while taking Nitozol?

A: Yes, regulatory documents specifically advise against consuming grapefruit or grapefruit juice when taking the oral tablets. This is because grapefruit can increase the concentration of the drug in the bloodstream, which may potentially raise the risk of experiencing side effects.

Q: Are there any studies comparing Nitozol's effectiveness to older drugs?

A: Some studies on topical Nitozol have included comparative research. For example, some reports indicate that the cream showed equivalent effectiveness to clotrimazole 1% cream over a four-week period for certain fungal infections.

Q: Does Nitozol have any effect on blood pressure?

A: Regulatory labeling for the oral tablets lists orthostatic hypotension as a reported adverse reaction. This refers to a drop in blood pressure that can occur when a person stands up too quickly.

Q: Can Nitozol interact with vitamins or mineral supplements?

A: Because Nitozol is a potent CYP3A4 inhibitor, official information advises caution regarding potential interactions with all over-the-counter medicines, vitamins, mineral supplements, and herbal products.

Q: Does Nitozol need to be stored in a special way?

A: Official instructions mandate that the medicine be stored at a controlled room temperature, typically between 20 C and 25 C. It should be kept in its original container, tightly closed, and protected from moisture and light.

Q: Are there any visual side effects associated with Nitozol?

A: Regulatory labeling for the oral tablets lists photophobia, or an increased sensitivity to light, as a reported adverse reaction related to the eyes.

Q: Does taking Nitozol affect my ability to drive or operate machinery?

A: Official information suggests that topical forms have no or a negligible influence on the ability to drive or operate machinery. However, for the oral tablets, the possibility of adverse effects like dizziness or drowsiness may require caution while performing complex tasks.

Q: Are there different strengths or formulations of Nitozol?

A: Yes, official product information confirms that Nitozol is supplied in various strengths and forms. These include 200 mg oral tablets, as well as topical products such as a 2% cream and a 2% shampoo.

How should Nitozol be stored and disposed of?

How to Store and Dispose of Nitozol?

Strictly adhere to the following official requirements for storing and disposing of Nitozol.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep the medicine in its original container, tightly closed, to protect it from moisture.
Child Safety	Store securely out of the sight and reach of children and pets.

Disposal Instructions

Do not flush Nitozol down the toilet or pour it down a drain unless specifically instructed to do so. The preferred disposal method is using an authorized drug take-back program or disposal service, such as those offered by pharmacies or law enforcement. If a take-back program is unavailable, mix the medicine with an unappealing substance (like dirt or used coffee grounds), seal the mixture in a bag, and discard it in the household trash. Do not crush the medicine before disposal.

Nitozol